Welcome to our dedicated page for CURATIVE BIOTECHNLOGY news (Ticker: CUBT), a resource for investors and traders seeking the latest updates and insights on CURATIVE BIOTECHNLOGY stock.
Curative Biotechnology, Inc. develops biomedical therapies with a current focus on degenerative eye diseases. Company news centers on its metformin-based topical ophthalmic formulation, a program supported by a worldwide exclusive license from the National Eye Institute at the NIH and a Cooperative Research and Development Agreement with the NEI. Updates also cover research agreements, clinical-supply manufacturing for sterile ophthalmic drops, and translational work spanning age-related macular degeneration and veterinary retinal degeneration models.
Recurring corporate developments include capital-structure actions such as the completed reverse stock split, strategic and financial advisory engagements, board and clinical-development governance updates, and material agreements tied to the company’s ophthalmology platform.
Curative Biotechnology (OTC: CUBT) announced a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) on March 21, 2022. This collaboration aims to evaluate Curative's proprietary ocular metformin formulation for treating Age-Related Macular Degeneration (AMD), a leading cause of vision loss. The CRADA will last three years, with research under the supervision of Dr. Emily Chew from NEI, potentially addressing unmet medical needs in AMD therapy.
Curative Biotechnology (CUBT) announced a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) to study its ocular metformin formulation for treating Age-Related Macular Degeneration (AMD). The agreement, effective for three years, aims to address the unmet therapeutic needs for AMD, a leading cause of vision loss. Under the leadership of Dr. Emily Chew, the collaboration will explore clinical evaluations of this novel therapy.
Curative Biotechnology (CUBT) has advanced its metformin eye drop formulations into ocular tolerance evaluation, marking a critical step toward human clinical trials. The studies will assess tolerability and pharmacokinetics, focusing on safety and ocular tissue distribution. This research will support future Good Laboratory Practice toxicology studies required for an Investigational New Drug (IND) filing. As part of the evaluation, metformin's plasma concentration will also be measured to ensure systemic safety. The company's innovative approach targets rare diseases, aiming for accelerated development paths.
Curative Biotechnology (OTC: CUBT) has announced the initiation of ocular tolerance evaluations for various metformin eye drop formulations, marking a progression towards human clinical trials. These studies will assess tolerability and pharmacokinetics, crucial for optimizing the formulation and ensuring safety for future IND filing. The research includes monitoring metformin plasma concentration to evaluate systemic exposure, alongside ophthalmic examinations and histopathological analysis. This advancement aligns with the company's focus on developing novel treatments for rare diseases.
Curative Biotechnology (CUBT) announced Dr. Catherine Sohn's appointment as a Special Advisor to its Board of Directors on October 12, 2021. Dr. Sohn, with over 30 years of biopharmaceutical experience, will oversee the company's infectious disease and macular degeneration programs. Paul Michaels, Chairman, emphasized her strategic background in vaccine development, particularly for the next-generation COVID-19 vaccine targeting kidney failure patients. This appointment aims to accelerate Curative's novel treatments for rare diseases and conditions, including a promising rabies therapeutic.
Curative Biotechnology (CUBT) has expanded its licensing agreement with Mid-Atlantic BioTherapeutics to include the development of a next-generation COVID-19 vaccine targeting kidney failure patients. This initiative addresses the need for tailored vaccines for immunocompromised individuals, who often have poor responses to existing vaccines. Curative Biotech also holds worldwide rights to develop IMT504 for treating symptomatic rabies, with orphan drug designation received in the US. The company aims to enhance its clinical development team in upcoming announcements.
Curative Biotechnology (CUBT) has entered into a licensing agreement with Mid-Atlantic BioTherapeutics (MABT) to develop a next-generation COVID-19 vaccine specifically targeting kidney failure patients, who are particularly vulnerable to severe COVID-19. This new vaccine will utilize IMT504 as an adjuvant in its formulation. The partnership expands Curative Biotech's portfolio, which already includes treatments for rabies and degenerative eye diseases. The press release highlights the urgent need for tailored vaccines for immunocompromised populations, with implications for both public health and potential market opportunities.
Curative Biotechnology, Inc. (OTC: CUBT) has appointed Dr. Nicholas Boulis, MD/PhD, to its Scientific and Clinical Advisory Board, enhancing its clinical program for a CD56 monoclonal antibody drug conjugate aiming to treat glioblastoma. Dr. Boulis, affiliated with Emory University and renowned for his expertise in neural gene therapy, is expected to work alongside Dr. Dimiter Dimitrov, the lead inventor, to advance the glioblastoma program. The company focuses on innovative treatments for rare diseases, aiming for accelerated development paths.
Curative Biotechnology (OTC: CUBT) announced that Marc Drimer, CPA, has joined its Board of Directors as an independent director and Chairman of the Audit Committee. With over 35 years of experience in corporate governance and finance, Drimer has had significant roles in international firms. His expertise includes financial operations and managing public offerings. Chairman Paul M. Michaels noted that Drimer's addition marks a vital milestone for the company as it seeks to explore capital market opportunities and advance its therapeutic pipeline aimed at rare diseases.
Curative Biotechnology (CUBT) released its Q1 quarterly report for the period ending March 31, 2021. Key highlights include a significant increase in cash reserves from $160,607 to $564,546 and a reduction in debt from $528,893 to $75,373. The company successfully converted Series A and B Preferred shares to Common, strengthening its equity structure. The management team has expanded, adding seasoned professionals to direct its therapeutic development efforts, particularly in rare diseases including rabies and glioblastoma. Curative Biotech is set to file an IND with the FDA for a new retinal degeneration treatment by year-end.